<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03109158</url>
  </required_header>
  <id_info>
    <org_study_id>NC-6004-008</org_study_id>
    <nct_id>NCT03109158</nct_id>
  </id_info>
  <brief_title>NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</brief_title>
  <official_title>Phase I/II Clinical Trial of NC-6004 in Combination With 5-FU and Cetuximab as First-line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NanoCarrier Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NanoCarrier Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1 of this study will establish a recommended Phase II (RPII) dose for the triplet
      combination of NC-6004 plus 5-Fluorouracil (5-FU) and cetuximab. Part 2 will provide the
      efficacy signal of the triplet combination in this patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NC-6004 is a polymeric micelle-containing cisplatin as an active moiety. The nanoparticle
      provides sustained release of the active moiety and utilizes the enhanced permeability and
      retention effect to target release of platinum to tumors. Currently available nonclinical
      data and enhanced pharmacokinetics suggest that NC-6004 has the potential to be more active
      than cisplatin, with increased tolerability.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">March 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open-Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>RPII dose for the combination of NC-6004 plus 5-FU plus cetuximab.</measure>
    <time_frame>Up to day 90</time_frame>
    <description>Part 1: To determine dose limiting toxicities and the RPII dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival in patients following treatment with NC-6004 plus 5-FU plus cetuximab.</measure>
    <time_frame>Up to day 90</time_frame>
    <description>Part 2: To determine the median PFS in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after treatment with NC-6004 plus cetuximab plus 5-FU.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to day 90</time_frame>
    <description>To evaluate overall response rate (ORR), duration of response (DOR), disease control rate (DCR = complete response [CR] + partial response [PR] +stable disease), duration of stable disease (DSD), and overall survival (OS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Up to day 90</time_frame>
    <description>Least squares mean estimates for health-related quality of life (HRQOL) scores over time</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence and severity of AEs and laboratory abnormalities</measure>
    <time_frame>Up to day 90</time_frame>
    <description>Incidence and severity of AEs and laboratory abnormalities, according to the NCI CTCAE v4.03 criteria.</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of SAEs and treatment discontinuations due to AEs</measure>
    <time_frame>Up to day 90</time_frame>
    <description>Adverse events will be summarized by dose level, in subsets of all TEAEs, and by all treatment-related AEs. Clinical laboratory and vital sign measurements will be summarized by dose level and change from baseline.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <arm_group>
    <arm_group_label>NC-6004 and 5-FU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I, continual reassessment method, dose-escalation study to determine the maximum tolerated dose (MTD) and an RPII dose of NC-6004 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
In Part 1, patients will be assigned to receive cetuximab followed by NC-6004 and 5-FU.
Phase II, adaptive, open-label expansion study evaluating the activity, safety, and tolerability of NC-6004 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck at the RPII dose identified in Part 1.
In Part 2, all patients will receive NC-6004 at the RPII dose established in Part 1, in combination with cetuximab and 5-FU according to the same schedule as used in Part 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NC-6004</intervention_name>
    <description>NC-6004 provided by NanoCarrier</description>
    <arm_group_label>NC-6004 and 5-FU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Commercially Available</description>
    <arm_group_label>NC-6004 and 5-FU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>Commercially Available</description>
    <arm_group_label>NC-6004 and 5-FU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of stage III/IV recurrent and/or
             metastatic squamous cell carcinoma of the head and neck not suited for local therapy

          -  Measurable disease, as defined by RECIST v1.1

          -  ECOG performance status 0-1

          -  Adequate bone marrow reserve

          -  Adequate liver and renal function

          -  Have a negative pregnancy test result at Screening for females of childbearing
             potential

          -  Male patients must agree to use a condom during treatment and for 90 days after dosing
             and must agree not to donate sperm for 90 days after dosing

          -  Women of childbearing potential are willing to agree to use 1 of the study-defined
             effective methods of birth control from the time of study entry to 6 months after the
             last day of treatment

          -  Reasonably recovered from preceding major surgery as judged by the investigator or no
             major surgery within 4 weeks prior to the start of Day 1 treatment

        Exclusion Criteria:

          -  Nasopharyngeal carcinoma

          -  Prior systemic chemotherapy, except if given as part of a multimodal treatment for
             locally advanced disease which was completed more than 3 months before Day 1 or more
             than 6 months prior to Day 1 if platinum-based

          -  Concomitant anticancer therapy, systemic immune therapy, or hormonal therapy as cancer
             therapy

          -  Unresolved toxicity from all radiation, adjuvant/ neoadjuvant chemotherapy, other
             targeted treatment including investigational treatment

          -  History of thrombocytopenia with complications

          -  Known hypersensitivity to platinum compounds

          -  Pregnant or breastfeeding

          -  Active infection (infection requiring intravenous antibiotics)

          -  Uncontrolled hypertension

          -  Malignancies other than head and neck cancer within 5 years prior to Day 1 of
             treatment, with the exception of those with a negligible risk of metastasis or death
             treated with expected curative outcome

          -  Signs or symptoms of organ failure, major chronic illnesses other than cancer, or any
             concomitant medical or social conditions which, in the opinion of the investigator,
             make it undesirable for the patient to participate in the study, or which could
             jeopardize compliance with the protocol

          -  Have experienced any of the following within the 6-month period prior to Screening:
             unstable angina pectoris, clinically significant coronary artery disease,
             cerebrovascular accident, transient ischemic attack, cardiac failure with known
             ejection fraction less than 40%, or cardiac arrhythmia

          -  Any investigational treatment within 30 days or 5 half-lives, whichever is longer, of
             Day 1 of treatment

          -  Patient is unwilling or unable to comply with study procedures, or is planning to take
             vacation for 7 or more consecutive days during the treatment phase of the study
             without prior consent from the medical monitor

          -  Any other medical or social condition that, in the opinion of the investigator, would
             not permit the patient to complete the study or sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilaria Bottesini</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_contact>
    <last_name>Ilaria Bottesini</last_name>
    <phone>00390396011524</phone>
    <email>ilaria.bottesini@ppdi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute, Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322-1013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intermountain Precision Genomics</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-7320</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complex Oncology Center - Shumen EOOD</name>
      <address>
        <city>Shumen</city>
        <zip>9700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Serdika EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1618</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tolna Megyei Balassa Janos Korhaz</name>
      <address>
        <city>Szekszárd</city>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coltea Clinical Hospital</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prof Dr I Chiricuta Institute of Oncology</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Center Sfantul Nectarie</name>
      <address>
        <city>Craiova</city>
        <zip>200347</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Euroclinic Oncology Center SRL</name>
      <address>
        <city>Iaşi</city>
        <zip>700106</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institutul Regional de Oncologie Iasi</name>
      <address>
        <city>Iaşi</city>
        <zip>700483</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Bottesini</last_name>
      <email>ilaria.bottesini@ppdi.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Hungary</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>squamous cell carcinoma</keyword>
  <keyword>head</keyword>
  <keyword>neck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

